Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is a biotechnology company with a positive outlook on the development of their proprietary psychedelic treatment. With strong Phase II and III trial results and a growing acceptance in the medical community, the company has a valuable intellectual property position. However, there are still risks and uncertainties surrounding regulatory hurdles and potential disruptions to clinical trials. Nonetheless, the company is expected to file an NDA and has potential for partnerships outside of the US.

Bears say

Compass Pathways is heavily dependent on the success of their experimental drug, COMP360, for treatment-resistant depression (TRD). While they anticipate favorable payer responses and have a strong data package, there are still significant risks associated with successfully navigating the FDA approval process and building a commercial infrastructure. Additionally, the company is facing significant competition and financing challenges, which could impact their potential for success in the market. Overall, there is a lack of certainty and potential obstacles that make the future success of this company uncertain and risky, leading to the negative outlook on its stock.

COMPASS Pathways (CMPS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.